REDEMPLO is the first and only FDA-approved medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, often resulting in a reduced quality of life The FDA approval is based on positive results from the Phase 3 PALISADE study where REDEMPLO... Read More

PASADENA, Calif. / Nov 06, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc . (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2025, at 4:30 p.m. ET to discuss its financial results for the 2025 fiscal year ended September 30, 2025. Webcast and Conference Call Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section... Read More

PASADENA, Calif. / Nov 04, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: American Heart Association (AHA) Scientific Sessions 2025 – November 7-10, 2025 Title: Rationale and Design: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Zodasiran in Adolescents and Adults with... Read More

PASADENA, Calif. / Oct 28, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 24, 2025, the Company’s Board of Directors approved “inducement” grants to 84 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 127,230 restricted stock units.... Read More

PASADENA, Calif. / Oct 21, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announced on September 2, 2025, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.... Read More

ARO-DIMER-PA is designed to selectively silence the expression of two genes with a single RNAi molecule using Arrowhead’s proprietary TRiM TM technology In preclinical studies ARO-DIMER-PA potently lowered serum PCSK9 and APOC3, and ameliorated high levels of non-HDL-cholesterol, LDL-cholesterol, and triglycerides in dyslipidemic nonhuman primates PASADENA, Calif. / Oct 07, 2025 / Business Wire / Arrowhead Pharmaceuticals,... Read More

PASADENA, Calif. / Sep 11, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc., to declare that Ionis’s United States Patent No. 9,593,333 (“the ’333 patent”) is invalid and not infringed by Arrowhead’s planned commercialization of... Read More

In preclinical studies presented today at the RNA Leaders USA Congress 2025, investigational ARO-MAPT demonstrated potent and long-lasting MAPT mRNA and Tau protein suppression with uniform distribution throughout the CNS after subcutaneous administration in non-human primates PASADENA, Calif. / Sep 10, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for... Read More

Upon closing, Arrowhead will receive an upfront payment of $200 million Novartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy for the treatment of synucleinopathies, such as Parkinson’s Disease, plus additional collaboration targets PASADENA, Calif. / Sep 02, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and... Read More

PASADENA, Calif. / Aug 27, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Society of Cardiology (ESC) Congress 2025 – August 29 - September 1, 2025 Title: A Randomized, Placebo-controlled Phase 3 Study of Plozasiran in Patients With FCS: Interim Analysis of Open Label Extension of PALISADE at 1 Year... Read More

Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding The remainder of the recently earned $100 million milestone, or approximately $50 million, will be received in cash Sarepta’s remaining holdings of Arrowhead stock were sold today in a separate negotiated block trade PASADENA, Calif.... Read More

Conference Call and Webcast Today, August 7, 2025, at 4:30 p.m. ET PASADENA, Calif. / Aug 07, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to achieve strong execution in discovery, clinical... Read More

Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead, which was previously granted rights to investigational plozasiran in Greater China Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering potential treatment to people... Read More

Milestone earned upon reaching first enrollment target in a Phase 1/2 study of ARO-DM1 for the treatment of type 1 myotonic dystrophy PASADENA, Calif. / Jul 28, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was triggered when Arrowhead reached the first of two prespecified... Read More

PASADENA, Calif. / Jul 24, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 22, 2025, the Company’s Board of Directors approved “inducement” grants to 38 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 52,680 restricted stock units. The... Read More

PASADENA, Calif. / Jul 23, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today issued a statement to address questions about the status of its ongoing Exclusive License and Collaboration Agreement with Sarepta Therapeutics. Arrowhead continues to conduct clinical and non-clinical studies as stipulated in the agreement, and it expects Sarepta to continue to meet its required financial obligations.... Read More

PASADENA, Calif. / Jul 21, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 third quarter ended June 30, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors... Read More

Zodasiran targets ANGPLT3, an emerging therapeutic target to treat HoFH and other dyslipidemias YOSEMITE Phase 3 study further enhances Arrowhead’s late-stage pipeline of RNAi-based cardiometabolic candidates PASADENA, Calif. / Jul 08, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s... Read More

Study completion anticipated in mid-2026 with subsequent data readout and regulatory submissions for treatment of severe hypertriglyceridemia PASADENA, Calif. / Jun 23, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company’s global Phase 3 clinical studies designed to support regulatory submissions for marketing... Read More

ARO-ALK7 is the first investigational RNAi therapeutic to enter clinical studies that targets a gene expressed in adipose tissue Study initiation highlights Arrowhead’s leadership in the delivery of siRNA to multiple tissues and cell types throughout the body utilizing its proprietary and differentiated Targeted RNAi Molecule (TRiM™) platform In preclinical studies, ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7)... Read More

PASADENA, Calif. / May 29, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc . (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: Jefferies Global Healthcare Conference – June 4-5, 2025 Type: Fireside Chat Presentation Date/Time: June 4, 2025, 9:20 a.m. EDT 46 th Annual Goldman Sachs Global Healthcare Conference – June 9-11, 2025 Type: Fireside Chat Presentation... Read More

Conference Call and Webcast Today, May 12, 2025, at 4:30 p.m. ET PASADENA, Calif. / May 12, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead is in a strong and stable position as a business, and we have... Read More

PASADENA, Calif. / May 07, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securities 2025 Health Care Conference – May 13-15, 2025 Type: Fireside Chat Presentation Date/Time: May 14, 2025, 11:20 a.m. PDT 2025 RBC Capital Markets Global Healthcare – May 20-21, 2025 Type: Fireside Chat Presentation... Read More

PASADENA, Calif. / Apr 30, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors... Read More

PASADENA, Calif. / Apr 15, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead’s Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company’s new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist... Read More

ARO-C3 achieved deep and sustained reductions in alternative pathway complement activity and proteinuria Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24 Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24 PASADENA, Calif. / Mar 10, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase... Read More

ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies Data highlight Arrowhead’s leadership in the use of RNA interference to potentially treat Obesity PASADENA, Calif. / Mar 06, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today... Read More

New Patient Resource Hub: Arrowhead expands its We’ll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides Amplifying Patient Voices: The Spotlight on FCS white paper shares real patient experiences,... Read More

PASADENA, Calif. / Feb 25, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being developed as a potential treatment for obesity. The results were presented in a poster at the Keystone Symposia on Obesity and Adipose Tissue held February 23–26,... Read More

Conference Call and Webcast Today, February 10, 2025, at 4:30 p.m. ET PASADENA, Calif. / Feb 10, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. “During the recent period, Arrowhead signed and closed a... Read More

PASADENA, Calif. / Feb 10, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other... Read More

PASADENA, Calif. / Jan 22, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the... Read More

The New Drug Application is based on positive results from the Phase 3 PALISADE study People living with familial chylomicronemia syndrome have extremely high triglyceride levels and a substantially higher risk of developing acute pancreatitis and associated long-term complications, including poor quality of life PASADENA, Calif. / Jan 17, 2025 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced... Read More

ARO-INHBE targets a known pathway that signals the body to store fat in adipose tissue In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies PASADENA, Calif. / Dec 23, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects... Read More

PASADENA, Calif. / Dec 19, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024, the Company’s Board of Directors approved “inducement” grants to 20 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 44,350 restricted stock units.... Read More

Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway PASADENA, Calif. / Dec 11, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic targeting complement factor B being... Read More

In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle PASADENA, Calif. / Dec 03, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the... Read More

PASADENA, Calif. / Dec 02, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 36th Annual Healthcare Conference – December 3-5, 2024 Type: Fireside Chat Presentation Date/Time: December 3, 2024, 1:30 p.m. EST 7 th Annual Evercore ISI HealthCONx Conference – December 3-5, 2024 Type: Fireside Chat Presentation... Read More

Conference Call and Webcast Today, November 26, 2024, at 4:30 p.m. ET PASADENA, Calif. / Nov 26, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results. “Arrowhead is well positioned, both individually and with partners,... Read More

Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five years Arrowhead has potential to receive an additional $300 million in near-term clinical trial enrollment-related milestone payments and is eligible for future potential milestone payments up to $10 billion and royalties on sales... Read More

Plozasiran induced deep and sustained reductions in triglycerides and impacted a wide spectrum of lipoproteins that may be involved with atherosclerotic cardiovascular disease Similar responses were observed in patients with genetically confirmed and clinically diagnosed FCS Mean reductions in triglycerides of up to -73% in patients from MUIR and -86% in patients from SHASTA-2 with favorable reductions in remnant cholesterol... Read More

The New Drug Application is based on positive results from the Phase 3 PALISADE study People living with familial chylomicronemia syndrome have extremely high triglyceride levels and a substantially higher risk of developing acute pancreatitis and associated long-term complications, including poor quality of life There are currently no FDA approved therapies to treat familial chylomicronemia syndrome PASADENA, Calif. / Nov... Read More

PASADENA, Calif. / Nov 05, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on November 26, 2024, at 4:30 p.m. ET to discuss its financial results for the 2024 fiscal year ended September 30, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section... Read More

PASADENA, Calif. / Nov 04, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 15 th Annual American Conference on Pharmacometrics (ACoP 2024) – November 10-13, 2024 Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemia Presenter:... Read More

The launch of this campaign is about imagining a future where ongoing research, support, and heightened disease awareness for people with extremely high triglycerides come together to change lives — 'We'll Get There Soon' PASADENA, Calif. / Nov 01, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today, on... Read More

PASADENA, Calif. / Oct 14, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company’s Board of Directors approved “inducement” grants to 34 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 66,750 restricted stock units.... Read More

In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may preserve lean muscle mass compared to currently approved obesity therapies PASADENA, Calif. / Sep 23, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA... Read More

PALISADE Phase 3 results demonstrate plozasiran reduced triglycerides by 80% from baseline and reduced the risk of developing acute pancreatitis by 83% in patients with genetically confirmed and clinically diagnosed FCS 1 PASADENA, Calif. / Sep 10, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy... Read More

Plozasiran reduced triglycerides by 80% from baseline and reduced the risk of developing acute pancreatitis by 83% Similar responses were observed in patients with genetically confirmed and clinically diagnosed FCS Based on these findings, Arrowhead plans to file a New Drug Application by year-end 2024 PALISADE results simultaneously published in The New England Journal of Medicine Company hosting a virtual analyst and... Read More

Company hosting a virtual analyst and investor event on September 3, 2024, at 8:00 am EDT to discuss results PASADENA, Calif. / Aug 21, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present new Phase 3 clinical data from the PALISADE study of plozasiran (ARO-APOC3) at the European Society of Cardiology (ESC) Congress 2024, being held in London August 30 through September... Read More

Company hosting an obesity/metabolic R&D webinar today, August 14, 2024, at 2:00 pm ET as Part IV of the 2024 Summer Series of R&D Webinars PASADENA, Calif. / Aug 14, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data and detailed its plans to advance two next generation RNAi-based candidates, ARO-INHBE and ARO-ALK7, into upcoming clinical studies for the treatment of... Read More

Conference Call and Webcast Today, August 8, 2024, at 4:30 p.m. ET PASADENA, Calif. / Aug 08, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 third quarter ended June 30, 2024. The Company is hosting a conference call today, August 8, 2024, at 4:30 p.m. ET to discuss the results. “Arrowhead had a very productive quarter with several high-profile... Read More

- Balance sheet strengthened with long-term, non-dilutive capital - $400 million funded at close with the potential to draw an additional $100 million - Immediately enhances Arrowhead’s ability to advance plozasiran towards a 2025 launch - Expands possibilities to fund innovation and growth across Arrowhead’s robust and diverse pipeline of RNAi therapeutics PASADENA, Calif. / Aug 08, 2024 / Business Wire / Arrowhead... Read More

PASADENA, Calif. / Jul 29, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 25, 2024, the Company’s Board of Directors approved “inducement” grants to 33 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 60,900 restricted stock units. The... Read More

PASADENA, Calif. / Jul 24, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 8, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ended June 30, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at... Read More

Based on promising results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical studies of plozasiran including PALISADE in patients with familial chylomicronemia syndrome and the SHASTA studies in patients with severe... Read More

PASADENA, Calif. / Jun 24, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84 th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually. The preclinical results demonstrate that... Read More

Plozasiran achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10 Plozasiran achieved a statistically significant reduction in incidence of acute pancreatitis versus placebo Plozasiran is the company’s first investigational RNAi-based therapy to show clinical efficacy in a Phase 3 study Arrowhead plans to highlight recent data for its cardiometabolic... Read More

PASADENA, Calif. / May 31, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 16 th European Glaucoma Society (EGS) Congress – June 1-4, 2024 Title: Development and Characterization of Trabecular Meshwork Targeted RNAi Molecule Platform via Intracameral Administration for Glaucoma Date/Time: June 2, 2024, 10:30 a.m. IST... Read More

Zodasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins across all dose levels at Week 24 Data presented at European Atherosclerosis Society 92 nd Congress and simultaneously published in the New England Journal of Medicine PASADENA, Calif. / May 29, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized... Read More

Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol Data presented at European Atherosclerosis Society 92 nd Congress and simultaneously published in the New England Journal of Medicine PASADENA, Calif. / May 28, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized... Read More

ARO-RAGE reduced serum sRAGE by up to 88% in patients with asthma Additional promising results presented on two preclinical stage programs targeting thymic stromal lymphopoietin (TSLP) and influenza A viruses PASADENA, Calif. / May 20, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of... Read More

Conference Call and Webcast Today, May 9, 2024, at 4:30 p.m. ET PASADENA, Calif. / May 09, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024. The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m. ET to discuss the results. Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said:... Read More

PASADENA, Calif. / May 02, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX). This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN). Pursuant to its 2016 agreement with Amgen and 2022 agreement with... Read More

PASADENA, Calif. / Apr 29, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024 Type: Fireside Chat Presentation Date/Time: May 14, 2024, 9:30 a.m. EDT BofA Securities 2024 Healthcare Conference – May 13-16, 2024 Type: Fireside Chat Presentation... Read More

PASADENA, Calif. / Apr 26, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiM TM ) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature... Read More

PASADENA, Calif. / Apr 24, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at... Read More

PASADENA, Calif. / Apr 24, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial ( NCT06209177 ) of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement mediated kidney disease. James Hamilton, M.D., MBA, Chief of Discovery and Translational... Read More

Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia SHASTA-3 and SHASTA-4 Phase 3 studies to be initiated PASADENA, Calif. / Apr 07, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly... Read More

PASADENA, Calif. / Apr 01, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 30, 2024, the Company’s Board of Directors approved “inducement” grants to 32 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 31,700 restricted stock units. The... Read More

Expanded Access Program initiated to make investigational plozasiran available to patients with familial chylomicronemia syndrome New SHASTA-2 Phase 2 clinical data in patients with severe hypertriglyceridemia to be presented at ACC.24 PASADENA, Calif. / Mar 25, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational... Read More

- Preclinical data show ARO-DM1 reduces muscular DMPK expression and corrects spliceopathies, which could lead to improved muscle strength and function PASADENA, Calif. / Mar 08, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, placebo-controlled, dose-escalating study ( NCT06138743 ) to evaluate single and multiple... Read More

PASADENA, Calif. / Mar 04, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen's 44th Annual Health Care Conference – March 6, 2024 Type: Fireside Chat Presentation Date: March 6, 2024 Time: 9:10 a.m. ET Leerink Partners Global Biopharma Conference – March 13, 2024 Type: Fireside Chat Presentation Date: March 13,... Read More

Conference Call and Webcast Today, February 6, 2024, at 4:30 p.m. ET PASADENA, Calif. / Feb 06, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023. The Company is hosting a conference call today, February 6, 2024, at 4:30 p.m. ET to discuss the results. Webcast and Conference Call and Details Investors may access a... Read More

PASADENA, Calif. / Jan 22, 2024 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal first quarter ended December 31, 2023. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at... Read More

PASADENA, Calif. / Jan 05, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that on January 5, 2024, it closed the previously announced underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”). The offering was priced at $28.50 per share, and the company received gross proceeds of approximately $450.0 million, before deducting... Read More

PASADENA, Calif. / Jan 03, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”), offered at a price of $28.50 per share, before underwriting discounts. The offering is expected to close on or about January 5, 2024, subject to customary closing conditions.... Read More

PASADENA, Calif. / Dec 29, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc . (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 28, 2023, the Company’s Board of Directors approved “inducement” grants to 32 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 53,700 restricted stock units.... Read More

PASADENA, Calif. / Dec 21, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for complement mediated renal disease, such as immunoglobulin A nephropathy (IgAN), which is the most common... Read More

PASADENA, Calif. / Dec 20, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the upcoming 42 nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 8:15 a.m. PT. A webcast of the presentation may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. About Arrowhead Pharmaceuticals Arrowhead... Read More

Conference Call and Webcast Today, November 29, 2023, at 4:30 p.m. ET PASADENA, Calif. / Nov 29, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2023. The company is hosting a conference call today, November 29, 2023, at 4:30 p.m. ET to discuss the results. Webcast and Conference Call and Details Investors may access a live audio... Read More

PASADENA, Calif. / Nov 28, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. ARO-DM1 is designed to... Read More

PASADENA, Calif. / Nov 21, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference on November 30, 2023, at 1:00 p.m. ET. A webcast of the presentation may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. About Arrowhead... Read More

PASADENA, Calif. / Nov 16, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 29, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal year ended September 30, 2023. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm... Read More

Plozasiran achieved mean max reductions of up to 90% in APOC3 and 87% in triglycerides in patients with severe hypertriglyceridemia In patients with mixed dyslipidemia, mean max reduction in APOC3 was up to 89% leading to robust and durable reductions in multiple atherogenic lipoproteins Company will host a virtual analyst and investor event today, November 13, 2023, at 4:30 pm ET PASADENA, Calif. / Nov 13, 2023 / Business... Read More

PASADENA, Calif. / Nov 06, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on November 16, 2023, at 13:30 GMT. A webcast of the presentation may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. About Arrowhead Pharmaceuticals... Read More

Company will also host a virtual analyst and investor event on November 13, 2023 PASADENA, Calif. / Nov 02, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present new Phase 2 clinical data from the ongoing SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) at the American Heart Association (AHA) Scientific Sessions 2023, being... Read More

PASADENA, Calif. / Oct 03, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2023 Annual Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting – October 4-6, 2023 Date: October 5, 2023 Type: Poster Presentation Title: Preclinical Profile of ARO-SOD1, an siRNA Therapy for SOD1-ALS BMO Biopharma Spotlight... Read More

PASADENA, Calif. / Sep 27, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 26, 2023, the Company’s Board of Directors approved “inducement” grants to 47 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 81,350 restricted stock units.... Read More

Arrowhead Expands the Reach of RNAi Therapies to Address Diseases in the Lung Late-Breaking Clinical Data for ARO-RAGE for Treatment of Asthma Demonstrate Deep and Durable Gene Silencing Promising Preclinical Data Across Multiple Gene Targets Suggest Potentially Broad Applications for Arrowhead’s TRiM™ Platform PASADENA, Calif. / Sep 11, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced... Read More

PASADENA, Calif. / Sep 01, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Citi’s 18 th Annual BioPharma Conference – September 6, 2023 Type: 1-on-1 Investor Meetings European Respiratory Society (ERS) International Congress – September 9-13, 2023 Date: Sept. 10, 2023, 12:30-14:00 CEST Type: Poster Session 146 Title: A... Read More

Conference Call and Webcast Today, August 7, 2023 at 4:30 p.m. ET PASADENA, Calif. / Aug 07, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2023. The company is hosting a conference call today, Aug. 7, 2023, at 4:30 p.m. ET to discuss the results. Webcast and Conference Call and Details Investors may access a live audio... Read More

PASADENA, Calif. / Jul 24, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 third quarter ended June 30, 2023. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at... Read More

PASADENA, Calif. / Jul 17, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO-DUX4, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for patients with facioscapulohumeral muscular dystrophy (FSHD). ARO-DUX4 is the first clinical candidate... Read More

PASADENA, Calif. / Jul 06, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 4, 2023, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 56 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 96,550... Read More

PASADENA, Calif. / Jun 27, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to initiate a Phase 1 clinical trial of ARO-SOD1, an RNAi-based investigational medicine designed to reduce expression of superoxide dismutase 1 (SOD1) in the central nervous system (CNS) as a potential treatment for patients with amyotrophic lateral sclerosis (ALS)... Read More

Data Presented During Oral Session at EASL 2023 Demonstrate Fazirsiran’s Promising Impact on Key Markers of Liver Disease AATD-LD is a Rare Genetic Disease Affecting Children and Adults with no Approved Treatments Takeda and Arrowhead are Advancing Fazirsiran and Actively Enrolling in 160 patient Phase 3 REDWOOD Study PASADENA, Calif. / Jun 24, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today... Read More

PASADENA, Calif. / Jun 06, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Global Healthcare Conference – June 8, 2023 Type: Fireside chat presentation Goldman Sachs 44th Annual Global Healthcare Conference – June 12, 2023 Type: Fireside chat presentation European Association for the Study of the Liver (EASL)... Read More

New Clinical Data on ARO-RAGE Show Continued Dose Response with Single Inhaled Dose of 184 mg Achieving Mean Knockdown of 90% and Max of 95% Adipose Delivery Platform Achieved Single Dose Target Gene Silencing of Greater than 90% with Six Months of Duration in Non-human Primates Improved Hepatic Dimer Platform Achieves Equivalent or Better Knockdown of Two Target Genes with Longer Duration than Monomer Mixture in Non-human... Read More

44-48% Mean Reductions in LDL-C Achieved on Top of Continued Standard of Care Phase 3 Planning is Ongoing PASADENA, Calif. / May 23, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), in patients with... Read More

Primary Study Completion Anticipated in the Second Quarter of 2024 PASADENA, Calif. / May 16, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of its global Phase 3 clinical trial (PALISADE) evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome. The company anticipates that the primary portion of the study will be complete in the... Read More

PASADENA, Calif. / May 15, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2023 RBC Capital Markets Global Healthcare Conference – May 17, 2023 Type: Fireside chat presentation 91 st European Atherosclerosis Society Congress – May 23, 2023 Type: Poster presentation Title: ARO-ANG3, an Investigational RNAi... Read More

Conference Call and Webcast Today, May 2, 2023 at 4:30 p.m. ET PASADENA, Calif. / May 02, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2023. The company is hosting a conference call today, May 2, 2023, at 4:30 p.m. ET to discuss the results. Webcast and Conference Call and Details Investors may access a live audio webcast... Read More

Interim Results from Ongoing ARO-RAGE Phase 1/2 Study Demonstrate up to 90% Serum sRAGE Reduction with Mean Maximum Reduction of 80% after Two Doses Further Data to be Presented at Upcoming R&D Day PASADENA, Calif. / Apr 25, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2 clinical study of ARO-RAGE, the company’s investigational RNA interference... Read More

PASADENA, Calif. / Apr 18, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 2, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 second quarter ended March 31, 2023. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at... Read More

Event to include presentations on cardiometabolic, pulmonary, and newly announced central nervous system pipeline programs PASADENA, Calif. / Apr 12, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m. ET in New York City to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of... Read More

PASADENA, Calif. / Apr 04, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the first patient has been dosed in Takeda’s (TSE:4502/NYSE:TAK) Phase 3 REDWOOD clinical study of fazirsiran (TAK-999/ARO-AAT) for the treatment of alpha-1 antitrypsin deficiency associated liver disease (AATD-LD). The start of this pivotal study triggers a $40 million milestone payment from Takeda to... Read More

PASADENA, Calif. / Apr 03, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it earned a $30 million milestone payment from GSK (LSE/NYSE: GSK) following the start of GSK’s Phase 2b trial of GSK4532990, formerly called ARO-HSD, an investigational RNA interference (RNAi) therapeutic for the treatment of patients with non-alcoholic steatohepatitis (NASH). GSK4532990 is being developed... Read More

PASADENA, Calif. / Mar 31, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 29, 2023, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 31 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to... Read More

PASADENA, Calif. / Mar 20, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS). ARO-APOC3 was previously granted Orphan Drug designation by the FDA and the European Union. ARO-APOC3 is Arrowhead’s investigational... Read More

PASADENA, Calif. / Mar 03, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the respiratory/infections panel discussion on March 8, 2023, at 10:30 a.m. ET at the Cowen 43rd Annual Health Care Conference being held in Boston. A webcast link will be available on the Events and Presentations page under the Investors section of www.arrowheadpharma.com.... Read More

PASADENA, Calif. / Feb 15, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc . (NASDAQ: ARWR) announced today that it has gained rights to ARO-PNPLA3, formerly called JNJ-75220795, which was part of a 2018 research collaboration and option agreement between Arrowhead and Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. ARO-PNPLA3 is an investigational RNA interference (RNAi)... Read More

PASADENA, Calif. / Feb 06, 2023 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal first quarter ended December 31, 2022. The company is hosting a conference call today, February 6, 2023, at 4:30 p.m. ET to discuss the results. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at... Read More

PASADENA, Calif. / Feb 02, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MMP7, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF). “MMP7 is thought to play... Read More

PASADENA, Calif. / Jan 25, 2023 / Business Wire / Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended December 31, 2022. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at... Read More

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present on January 9, 2023, at 11:15 a.m. ET at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco. A webcast link will be available on the Events and Presentations page under the Investors section of www.arrowheadpharma.com . About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat... Read More

Announcement on January 9, 2023, with Webcast at 8:30 a.m. ET Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 9, 2023, at 8:30 a.m. ET, it will present topline data from the SEQUOIA Phase 2 study evaluating fazirsiran and provide an outline of a Phase 3 study that was co-developed with and will be run by Takeda. Fazirsiran is a potential first-in-class investigational RNA interference (RNAi)... Read More